Filing Flows › Comparisons › ICCC vs NTLA
Immucell vs Intellia Therapeutics: ICCC and NTLA compared
Immucell is the larger company: $7.2M of revenue in its latest quarter (Q2 2026) against $7.2M for Intellia Therapeutics (Q3 2026). Immucell is growing faster (+12% against -48% a year earlier).
Where the money goes: ICCC and NTLA
Immucell (ICCC) · Q2 2026
Immucell, Q2 2026: revenue $7.2M (+12% year over year), operating margin 26.9%, net earnings $1.8M, operating cash flow $3.0M. The chart follows the revenue to costs, profit and cash.
Intellia Therapeutics (NTLA) · Q3 2026
Intellia Therapeutics, Q3 2026: revenue $7.2M (-48% year over year), net loss $127M, operating cash flow −$85.4M. The chart follows the revenue to costs, profit and cash.
| Immucell (ICCC) | Intellia Therapeutics (NTLA) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $7.2M | $7.2M |
| Revenue growth, Y/Y | +12% | -48% |
| Gross margin | 33.9% | — |
| Operating margin | 26.9% | n/m |
| Net earnings | $1.8M | −$127M |
| Net margin | 25.5% | — |
| Operating cash flow | $3.0M | −$85.4M |
| Free cash flow | $2.3M | — |
Questions
Which is bigger, Immucell or Intellia Therapeutics?
Immucell is the larger company: $7.2M of revenue in its latest quarter (Q2 2026) against $7.2M for Intellia Therapeutics (Q3 2026).
Is Immucell or Intellia Therapeutics growing faster?
Immucell is growing faster (+12% against -48% a year earlier).
More: Immucell earnings · how Immucell makes money · Intellia Therapeutics earnings · how Intellia Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.